Standard TB treatment

PreclinicalSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Standard TB treatment is one of 65 small molecule programs targeting Lung Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung DiseaseActive, not recruiting

TuberculosisActive, not recruiting

Lung DiseasePreclinical

Active, not recruiting

TuberculosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Phase 3

17 2

Avelox

Bayer

Phase 3

12 3

Zyvox

Pfizer

Phase 3

10 4

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

25 5

Lamprene

Novartis

Phase 3

5 6

Sirturo

WWim Janssens

Phase 3

9 7

Levaquin

WWim Janssens

Phase 3

8 8

TB Alliance

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 9

Rayos

RRoxane Laboratories

Phase 3

1 10

Deltyba

Otsuka

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Lung Disease

NCT06909799

Clinical

Trials by Indication[1]

Lung Disease1 trial

A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease

Recruiting·TThe Aurum Institute NPC·N/A·NCT06909799·242 enrolled

Tuberculosis1 trial

Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00091936·592 enrolled

Treatment1 trial

Optimization of the TB Treatment Regimen Cascade

Completed·DDamien Foundation·Phase 3·NCT02153528·701 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Standard TB treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard TB treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard TB treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Standard TB treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lung Disease1 trial

Tuberculosis1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News